Clinical Guidance
NEW Retinal Vein Occlusion (RVO) Guidelines July 2015
These guidelines (July 2015) reflect changes in treatments, since the 2010 Interim RVO Guidelines. The guidelines provide evidence-based, clinical advice for the management of different aspects of RVO. The scope is limited to current diagnostic tools, management and service set-up and delivery to facilitate delivery of optimal care. They are aimed primarily at ophthalmologists but
Adult and Paediatric Anti-TNF policies for Severe Refractory Uveitis not approved for NHS England specialised commissioning
The Royal College of Ophthalmology (RCOphth) and the Clinical Reference Group for specialised ophthalmology services (CRG) regret having to report that the Adult and Paediatric Anti -TNF policies for Severe Refractory Uveitis have not been approved for specialised commissioning. Following this announcement we have met with NHS England to stress how detrimental this decision will
Response to NICE announcing their positive draft final guidance for EYLEA® for the treatment of visual impairment due to diabetic macular oedema (DMO)
The Royal College of Ophthalmologists welcomes the draft Final Appraisal Determination (FAD) from NICE recommending EYLEA (aflibercept) as a treatment option for patients with visual impairment due to diabetic macular oedema (DMO) and a central retinal thickness of >400 micrometers. We hope that this decision will become final and that clinical commissioning groups will support
Cataract Commissioning Guidance
The Cataract Commissioning Guidance has been written in response to public concern that wide variations across the country in commissioning policy for the treatment of cataract is effectively creating a “postcode lottery” and may be denying or delaying access to cataract surgery to some patients who need it. The last few decades have seen a
Field Safety Notice: Siemens Healthcare Diagnostics; samples containing fluorescein may show interference
Siemens Healthcare Diagnostics advises that if blood samples contain fluorescein it may interfere with the ADVIA Centaur® Systems TSH3 Ultra, Vitamin D and the ADVIA Centaur BRAHMS Procalcitonin assay tests. Evidence suggests that patients undergoing fluorescein angiography can retain small amounts of fluorescein dye in body fluids for up to 72 hours post angiography. Patients